Status:

TERMINATED

EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye

Lead Sponsor:

University Hospital Freiburg

Collaborating Sponsors:

Boehringer Ingelheim

Conditions:

Retinal Artery Occlusion

Fibrinolysis

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The aim of the EAGLE Study is to compare the efficacy of conservative medical treatment and local intraarterial fibrinolysis in patients with central retinal artery occlusion and to evaluate benefit a...

Eligibility Criteria

Inclusion

  • Subtotal central retinal artery occlusion or central retinal artery occlusion with choroidal hypoperfusion not lasting longer than 20h
  • Patients aged from 18 years to 75 years (in case of pre-existing blindness of other eye also older than 75 years)
  • Informed consent of the patient

Exclusion

  • Central retinal artery occlusion lasting longer than 20h
  • Eye diseases, namely branch retinal artery occlusion, cilioretinal arteries supplying the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy and elevated intraocular pressure (over 30 mmHg)
  • Systemic diseases, namely severe general diseases, systemic arterial hypertension (systolic pressure \> 200 mmHg), despite medical therapy, acute systemic inflammation (erythrocyte sedimentation rate \> 30 mm within the first hour/ C-reactive protein \> 1,0 mg/dl), antithrombin-III deficiency in case of thrombocytopenia (\< 100000 per ml): pathologic clotting time, acute pancreatitis with elevated pancreas enzymes
  • Medical History: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation within the last 4 weeks, therapy with marcumar/warfarin, allergic reaction to contrast agent, haemorrhagic diathesis, aneurysms, inflammatory vascular diseases (e.g., giant cell arteritis, Wegener´s granulomatosis), endocarditis, gastric ulcer
  • Patient participation in other studies during the prior 4 weeks
  • No willingness and ability of the patient to participate in all follow-up examinations
  • Pregnancy
  • Written consent not given
  • Patient is not mobile (bedridden)
  • Other conditions/ circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, no fixed abode)

Key Trial Info

Start Date :

September 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT00637468

Start Date

September 1 2002

Last Update

March 18 2008

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Universityhospital Graz

Graz, Austria

2

Universityhospital Innsbruck

Innsbruck, Austria

3

Allgemeines Krankenhaus Wien

Vienna, Austria

4

University Medical Center Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany